Preclinical studies suggest that PD-L1 expression in metastatic NB represents a crucial mechanism for limiting immune surveillance [15], and that combined immunotherapy with anti-PD-L1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated NB [38]. The gene discussed is CD4; the disease is neuroblastoma.